cero.bio (CERO): Prakiraan wutah bathi resik saben saham kanggo taun ngarep

Logo perusahaan publik CERo Therapeutics Holdings (CERO)

CERo Therapeutics (CERO) dominates the cell therapy segment through unique phagocytosis methods and robust patent protection. Analyst 12-month EPS growth targets reflect expectation dynamics, where the value of 75.70 corresponds to the current metric. Growth is supported by an elite group of scientists utilizing an academic approach and generous RSUs, as well as strict compliance with environmental regulations regarding biohazardous waste disposal.

CERo Therapeutics (CERO): Prakiraan wutah bathi resik saben saham kanggo taun ngarep saka 21.02.2024 nganti 08.11.2025

Ringkesan rincian data analitis CERo Therapeutics Holdings, Inc. (CERO)

Analisis fundamental perusahaan:CERO, CERo Therapeutics Holdings Inc.
Produk dadi CERo Therapeutics Holdings

This indicator aggregates daily changes in analysts' consensus earnings per share (EPS) forecasts, filtering out short-term volatility to identify a sustainable fundamental trend. The price action of the target net EPS growth rate allows for a real-time assessment of CERo Therapeutics (CERO) management's ability to meet clinical trial deadlines, separating genuine market expectations from speculative noise following the IPO.

Perusahaan pesaing